NAOV Nanovibronix, Inc. - 8-K

Item 5.02

Departure
of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On
December 24, 2025, the Board of Directors of ENvue Medical, Inc. (the “ Company ”) approved the amendment and
restatement of the 2024 Long Term Incentive Plan (as amended and restated, the “ Amended and Restated Plan ”).
The Amended and Restated Plan amends the definition of Awards (as defined in the Amended and Restated Plan), for Israeli law purposes,
to include restricted stock units, or such other Awards as may be granted under Section 102 (as defined in the Amended and Restated Plan)
to comply with certain Israeli tax laws and requirements. The Amended and Restated Plan further reflects certain non-material updates,
including but not limited to (i) certain
updates made in connection with the Company’s name change from “NanoVibronix, Inc.” to “ENvue Medical, Inc.”
and (ii) updates
as related to the First Amendment to the 2024 Long Term Incentive Plan, as approved
by the stockholders of the Company on December 4, 2025.

The
description of the Amended and Restated Plan is qualified in its entirety by reference to the full text of the Amended and Restated Plan,
filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01

Financial Statements
and Exhibits.

(d)
Exhibits

Exhibit
No.

Description

10.1

Amended and Restated 2024 Long Term Incentive Plan of ENvue Medical, Inc., dated as of December 24, 2025

104

Cover Page Interactive
Data File (embedded within the Inline XBRL document)